PhaseRx (PhaseRx) ROCE % : -208.20% (As of Sep. 2017)

View and export this data going back to 2016. Start your Free Trial

What is PhaseRx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PhaseRx's annualized ROCE % for the quarter that ended in Sep. 2017 was -208.20%.

PhaseRx ROCE % Historical Data

The historical data trend for PhaseRx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx ROCE % Chart

PhaseRx Annual Data

Trend

Dec14

Dec15

Dec16

ROCE %

PhaseRx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
ROCE %	Get a 7-Day Free Trial							-63.85	-79.75	-126.58	-159.61	-208.20

PhaseRx ROCE % Calculation

PhaseRx's annualized ROCE % for the fiscal year that ended in Dec. 2016 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2016 )		(A: Dec. 2015 )		(A: Dec. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2016 )		(A: Dec. 2015 )		(A: Dec. 2016 )
	=	-18.079	/	( ( (3.914 - 23.928)	+	(16.448 - 2.024) )	/ 2 )
	=	-18.079	/	( (-20.014	+	14.424)	/ 2 )
	=	-18.079	/	-2.795
	=	646.83 %

PhaseRx's ROCE % of for the quarter that ended in Sep. 2017 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2017 )		(Q: Jun. 2017 )		(Q: Sep. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2017 )		(Q: Jun. 2017 )		(Q: Sep. 2017 )
	=	-10.076	/	( ( (9.206 - 2.837)	+	(6.038 - 2.728) )	/ 2 )
	=	-10.076	/	( ( 6.369	+	3.31 )	/ 2 )
	=	-10.076	/	4.8395
	=	-208.20 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

PhaseRx (OTCPK:PZRXQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PhaseRx ROCE % Related Terms

Thank you for viewing the detailed overview of PhaseRx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseRx (PhaseRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119

Website

http://www.phaserx.com

PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.

Executives

Gordon Brandt	officer: Chief Medical Officer	410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr	director	300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio • 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm • 05-24-2016